Anticoagulants: Difference between revisions
Elcatracho (talk | contribs) |
Neil.m.young (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
[[File:Anticoagulants.png|thumb]] | [[File:Anticoagulants.png|thumb]] | ||
==Contraindications to Anticoagulation<ref>Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.</ref> | ==Contraindications to Anticoagulation<ref>Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.</ref>=== | ||
*Absolute: | *Absolute: | ||
**Active bleeding | **Active bleeding | ||
Revision as of 14:47, 3 April 2022
Contraindications to Anticoagulation[1]=
- Absolute:
- Active bleeding
- Severe bleeding diathesis or platelet count <20K
- Neurosurgery, ocular surgery, or intracranial bleeding in the last 10 days
- Relative:
- Mild-to-moderate bleeding diathesis or thrombocytopenia
- Brain metastases
- Recent major trauma
- Major abdominal surgery within the past 2 days
- GI or GU bleeding within the past 14 days
- Endocarditis
- Severe hypertension (>200/120mmHg) at presentation
Vitamin K Antagonist
Blocks activation of vitamin K dependent prothrombotic factors II, VII, IX, X and blocks synthesis of vitamin K dependent ANTI-thrombotic proteins C and S
Heparins
Bind to and activate antithrombin, which in turns inactivates factor Xa and thrombin
Factor Xa Inhibitors
Inhibits Factor Xa, leading to inactivation of thrombin
- Rivaroxaban (Xarelto)
- Apixaban (Eliquis)
- Fondaparinux
- Edoxaban
Direct Thrombin Inhibitors
Self-explanatory
See Also
References
- ↑ Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.